Anlon Healthcare shareholders approved a share swap to acquire stakes in Apiqo Organics and Bizotic Lifescience during the annual general meeting held on September 5, 2026. The company subsequently disclosed the finalized pricing mechanism for the associated preferential allotment, setting the issue price at ₹17.85 per equity share.

Pricing and Valuation Details

The company determined the floor price in accordance with Regulation 164 of the SEBI ICDR Regulations. The volume-weighted average price on the National Stock Exchange over the 90 trading days preceding the relevant date was ₹17.85, while the 10-day average stood at ₹14.99. Consequently, the higher figure of ₹17.85 was adopted as the floor price.

An independent registered valuer, CA Gaurang Agarwal, issued a revised valuation report dated September 1, 2026. The report determined the fair value of Anlon Healthcare’s equity shares at ₹17.85 per share. This alignment between the regulatory floor price and the independent fair value ensures compliance with Chapter V of the SEBI ICDR Regulations.

Allottee Disclosures

The disclosure identifies the ultimate beneficial owners for the proposed allottees under the preferential issue. Key entities include Unicorn Fund, controlled by Nisarg Prafulbhai Thakkar, and various Hindu Undivided Families (HUFs) such as Jignesh C Parekh HUF and Piyush Shah HUF. Corporate allottees include Mars Forge Private Limited and Vedant Engitech and Infrastructure Private Limited.

Regulatory Compliance

The company addressed observations from both the BSE and NSE regarding the initial AGM notice and corrigendum. A certificate from M/s. K.P. Ghelani & Associates, Company Secretaries, confirms that the preferential issue adheres to SEBI ICDR requirements. This disclosure supplements the AGM notice and corrigendum previously circulated to shareholders.

Anlon Healthcare shareholders approved key strategic resolutions including an enhancement of authorized share capital and a major preferential equity issuance to acquire Apiqo Organics Private Limited and Bizotic Lifescience Private Limited. The 13th Annual General Meeting was held on September 5, 2026, via video conference.

The meeting commenced at 11:10 am and concluded at 11:50 am. Punitkumar Rasadia, Chairman and Managing Director, presided over the proceedings. A total of 31 members were present. The company submitted the voting results and consolidated scrutinizer's report to BSE Limited and the National Stock Exchange of India Ltd pursuant to Section 108 of the Companies Act, 2013, and Rule 20 of the Companies (Management and Administration) Rules, 2014.

Key Resolutions Passed

Shareholders approved ordinary and special resolutions covering financial statements, director appointments, and corporate actions. The most material decisions involved expanding the capital structure to facilitate acquisitions.

Management Overview

Punitkumar Rasadia provided an overview of the company’s operations and financial performance for the fiscal year ended March 31, 2026. Naimish Bhatt, Chief Financial Officer, welcomed members and briefed them on participation procedures. Seven registered speakers raised questions, which were addressed by the management. Detailed queries were requested via email for comprehensive responses.

The statutory auditor, M/s R V D & Co., and secretarial auditor/scrutinizer, M/s K. P. Ghelani & Associates, were present. Their reports contained no qualifications or adverse remarks.